Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study)
Authors:
Open Access
- 1 December 2011
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (12) , E1982-E1989
Abstract
Context: The undercarboxylated form of the osteoblast-secreted protein osteocalcin has favorable effects on fat and glucose metabolism in mice. In human subjects, cross-sectional studies suggest a relevant association. Objective: We investigated whether changes in undercarboxylated osteocalcin (ucOC) during osteoporosis treatment are associated with changes in metabolic parameters. Design, Setting, Participants, and Interventions: We measured ucOC in sera from a subset of osteoporotic postmenopausal women who were treated with PTH(1-84) or alendronate (n = 64 and n = 33, respectively) during the Parathyroid Hormone and Alendronate study. Main Outcome Measures: We measured serum adiponectin, leptin, and insulin and analyzed existing data on body weight, fat mass, and serum glucose concentration. Three-month changes in ucOC levels were evaluated as predictors of 12-month changes in indices of fat and glucose metabolism. Results: ucOC levels increased with PTH(1-84) and decreased with alendronate administration (P ≤ 0.01 for both treatment groups). Three-month change in ucOC was inversely associated with 12-month changes in body weight (standardized β = −0.25, P = 0.04) and fat mass (β = −0.23, P = 0.06), after adjustment for the treatment group. Three-month change in ucOC was positively associated with a 12-month change in adiponectin (β = 0.30, P = 0.01), independent of change in fat mass. There were no interactions between treatment and change in ucOC on changes in weight, fat mass, or adiponectin. Conclusions: PTH(1-84) increases and alendronate decreases ucOC levels. Changes in ucOC induced by PTH(1-84) and alendronate are associated with changes in metabolic indices. These associations are consistent with observations from animal models and support a role for ucOC in the skeletal regulation of energy metabolism in humans.Keywords
This publication has 20 references indexed in Scilit:
- Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levelsEuropean Journal of Endocrinology, 2010
- Evidence for Osteocalcin Production by Adipose Tissue and Its Role in Human MetabolismThe Journal of Clinical Endocrinology & Metabolism, 2010
- Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitusOsteoporosis International, 2010
- Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individualsEuropean Journal of Endocrinology, 2009
- Plasma Osteocalcin Is Inversely Related to Fat Mass and Plasma Glucose in Elderly Swedish MenJournal of Bone and Mineral Research, 2009
- Association between Serum Osteocalcin and Markers of Metabolic PhenotypeThe Journal of Clinical Endocrinology & Metabolism, 2009
- Relationship between osteocalcin and glucose metabolism in postmenopausal womenClinica Chimica Acta, 2008
- Effect of Exogenous Intermittent Recombinant Human PTH 1–34 Administration and Chronic Endogenous Parathyroid Hormone Excess on Glucose Homeostasis and Insulin SensitivityHormone and Metabolic Research, 2008
- Plasma Acylation-Stimulating Protein, Adiponectin, Leptin, and Ghrelin before and after Weight Loss Induced by Gastric Bypass Surgery in Morbidly Obese SubjectsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, AdiponectinThe Journal of Clinical Endocrinology & Metabolism, 2001